In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 269-274

  Puhl, Matthew D ^a,b   Mintzopoulos, Dionyssios ^a,c   Jensen, J Eric ^a,c   Gillis, Timothy E ^a,c   Konopaske, Glenn T ^a,b   Kaufman, Marc J ^a,c   Coyle, Joseph T ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b Laboratory for Psychiatric and Molecular Neuroscience   (United States)

^c McLean Imaging Center   (United States)

Author keywords

Glutamate; Magnetic resonance imaging; Magnetic resonance spectroscopy; Schizophrenia; Serine racemase knockout mouse; Ventricular volume; Aminobutyric acid

Indexed keywords

ISOFLURANE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RACEMASE; SERINE; SERINE RACEMASE; UNCLASSIFIED DRUG; ISOMERASE;

ADULT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; GENETIC POLYMORPHISM; IN VIVO STUDY; MALE; MOUSE; MUTANT; NEUROCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, TRANSGENIC; RACEMASES AND EPIMERASES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84908576804     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.009     Document Type: Article

References (55)

1. Balu D.T., Basu A.C., Corradi J.P., Cacace A.M., Coyle J.T. The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol. Dis. 2012, 45(2):671-682.
2. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(26):E2400-E2409.
3. Basu A.C., Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 2009, 14(7):719-727.
4. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25(1):1-27.
5. Blum B.P., Mann J.J. The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol. 2002, 5(2):159-179.
6. Boretius S., Tammer R., Michaelis T., Brockmöller J., Frahm J. Halogenated volatile anesthetics alter brain metabolism as revelaed by proton magnetic resonance spectroscopy of mice in vivo. Neuroimage 2013, 69:244-255.
7. Brown M.B., Forsythe A.B. Robust tests for the equality of variances. J. Am. Stat. Assoc. 1974, 69(346):364-367.
8. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006, 39(Suppl. 1):S10-S14.
9. Coyle J.T. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox. Res. 2006, 10(3-4):221-233.
10. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1(2):183-189.
11. de la Fuente-Sandoval C., León-Ortiz P., Favila R., Stephano S., Mamo D., Ramírez-Bermúdez J., et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36(9):1781-1791.
12. de la Fuente-Sandoval C., León-Ortiz P., Azcárraga M., Stephano S., Favila R., Díaz-Galvis L., et al. Glutamate levels in the association striatum before and after 4weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013, 70(10):1057-1066.
13. DeLisi L.E., Szulc K.U., Bertisch H.C., Majcher M., Brown K. Understanding structural brain changes in schizophrenia. Dialogues Clin. Neurosci. 2006, 8(1):71-78.
14. Faustman W.O., Bardgett M., Faull K.F., Pfefferbaum A., Csernansky J.G. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol. Psychiatry 1999, 45(1):68-75.
15. Flaum M., O'Leary D.S., Swayze V.W., Miller D.D., Arndt S., Andreasen N.C. Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J. Psychiatr. Res. 1995, 29(4):261-276.
16. Frahm J., Merboldt K.D., Hänicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 1987, 72(3):502-508.
17. Goto N., Yoshimura R., Moriya J., Kakeda S., Ueda N., Ikenouchi-Sugita A., et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study. Schizophr. Res. 2009, 112(1-3):192-193.
18. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn. Reson. Med. 1993, 29(6):804-811.
19. Habl G., Zink M., Petroianu G., Bauer M., Schneider-Axmann T., von Wilmsdorff M., et al. Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. J. Neural Transm. 2009, 116(12):1657-1665.
20. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):585-594.
21. Javitt D.C. Glutamate and schizophrenia: Phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
22. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
23. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002, 62(5):743-755.
24. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69(5):449-459.
25. Kirov G., O'Donovan M.C., Owen M.J. Finding schizophrenia genes. J. Clin. Invest. 2005, 115(6):1440-1448.
26. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn. Reson. Med. 1990, 14(1):26-30.
27. Levene H. Robust tests for equality of variances. Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling 1960,278-292. Stanford University Press, Menlo Park, CA. I. Olkin, S.G. Ghurye, W. Hoeffding, W.G. Madow, H.B. Mann (Eds.).
28. Lewis D.A., Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int. Rev. Neurobiol. 2007, 78:109-131.
29. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31(5):234-242.
30. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., Panizzutti R. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 2008, 101(1-3):76-83.
31. Mathalon D.H., Sullivan E.V., Lim K.O., Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58(2):148-157.
32. Mathalon D.H., Pfefferbaum A., Lim K.O., Rosenbloom M.J., Sullivan E.V. Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch. Gen. Psychiatry 2003, 60(3):245-252.
33. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., et al. MRI anatomy of schizophrenia. Biol. Psychiatry 1999, 45(9):1099-1119.
34. McCarthy B.W., Gomes U.R., Neethling A.C., Shanley B.C., Taljaard J.J., Potgieter L., et al. gamma-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia. J. Neurochem. 1981, 36(4):1406-1408.
35. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17(8):2921-2927.
36. Ongür D., Pescot A.P., McCarthy J., Cohen B.M., Renshaw P.F. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 2010, 68(7):667-670.
37. Perälä J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsä E., Pirkola S., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 2007, 64(1):19-28.
38. Petryshen T.L., Middleton F.A., Kirby A., Aldinger K.A., Purcell S., Tahl A.R., et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol. Psychiatry 2005, 10(4):366-374.
39. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30(6):672-679.
40. Ripke S., Neale B.M., Corvin A., Walters J.T., Farh K.H., Holmans P.A., et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427.
41. Rowland L.M., Kontson K., West J., Edden R.A., Zhu H., Wijtenburg S.A., et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr. Bull. 2013, 39(5):1096-1104.
42. Shizukuishi T., Abe O., Aoki S. Diffusion tensor imaging analysis for psychiatric disorders. Magn. Reson. Med. Sci. 2013, 12(3):153-159.
43. Soher B.J., Young K., Bernstein A., Aygula Z., Maudsley A.A. GAVA: spectral simulation for in vivo MRS applications. J. Magn. Reson. 2007, 185(2):291-299.
44. Staal W.G., Hulshoff Pol H.E., Schnack H.G., van Haren N.E., Seifert N., Kahn R.S. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am. J. Psychiatry 2001, 158(7):1140-1142.
45. Steffek A.E., Haroutunian V., Meador-Woodruff J.H. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 2006, 17(11):1181-1185.
46. Tayoshi S., Nakataki M., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr. Res. 2010, 117(1):83-91.
47. Théberge J., Al-Seeman Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 2003, 160(12):2231-2233.
48. Tkác I., Starcuk Z., Choi I.Y., Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn. Reson. Med. 1999, 41(4):649-656.
49. Valette J., Guillermier M., Besret L., Hantraye P., Bloch G., Lebon V. Isoflurane strongly affects the diffusion of intracellular metabolites, as shown by 1H nuclear magnetic resonance spectroscopy of the monkey brain. J. Cereb. Blood Flow Metab. 2007, 27(3):588-596.
50. van der Heijden F.M., Tuinier S., Fekkes D., Sijben A.E., Kahn R.S., Verhoeven W.M. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur. Neuropsychopharmacol. 2004, 14(3):259-265.
51. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N., Harrison P.J., et al. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26(6):1657-1669.
52. Williams N.M., Preece A., Spurlock G., Norton N., Williams H.J., McCreadie R.G., et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol. Psychiatry 2004, 55(2):192-195.
53. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin A., Sullivan S.E., Neale J.H. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 1997, 69(1):174-181.
54. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 2010, 30(10):3777-3781.
55. Zimmer R., Teelken A.W., Meier K.D., Ackenheil M., Zander K.J. Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs. Prog. Neuropsychopharmacol. 1980, 4(6):613-620.